

Our promise

June 2025



For over 100 years, Novo Nordisk has developed innovative medicines for people living with serious chronic diseases including diabetes, obesity, rare disorders, and cardiovascular conditions.

The development of semaglutide is an example of our commitment to such innovation and is the foundational molecule, which serves as the primary ingredient for our prescription-only, FDA-approved medicines: Wegovy® (semaglutide) injection 2.4 mg, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and RYBELSUS® (semaglutide) tablets 7 mg or 14 mg.

Throughout our history, patient safety has been our top priority, and we've been closely monitoring how these medicines are being broadly discussed in mainstream and social media. As a part of our commitment to that priority, we are educating the public about the potential risks associated with compounded knockoffs, combating counterfeiters from endangering patients, providing training and education for the responsible use of our medicines, and ensuring that our business practices fulfill our promises to patients.

As a result of these unprecedented dynamics and high demand for semaglutide products, we believe it is our responsibility to continue to raise awareness around these issues and, ultimately, to support patient safety and positive clinical outcomes.

Unapproved knockoff or compounded "semaglutide"

With all doses of FDA-approved Wegovy® and Ozempic® fully available nationwide, it is illegal under US compounding laws to make or sell compounded "semaglutide," with rare exceptions. Any entity that mass produces or sells knockoff "semaglutide" is breaking the law and putting patient safety at risk.¹ Some compounded "semaglutide" can contain dangerous impurities, substances on the FDA's banned list, and unnecessary ingredients.^{2,3}

To evade the law, some compounders are offering "semaglutide" under the guise of "personalized" dose strengths and alternative routes of administration. Yet, there is no medical basis for the mass production of unapproved "personalized" compounded drugs. Customized doses of compounded "semaglutide" have never been tested in clinical trials and have never been approved by the FDA to be safe and effective. This means that there is no reliable evidence that customized doses (or dose escalation schedules) reduce side effects, improve efficacy, or are a minimal effective dose with acceptable safety profile.⁴ When it comes to versions that utilize alternative routes of administration, such as melting under your tongue or against your cheek, the likelihood that they will be effectively absorbed by your body is low.^{2,5}

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.

Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.

Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.

Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.



Nearly all “semaglutide” used in compounding is manufactured by foreign suppliers.⁶ The FDA has never authorized or approved the manufacturing processes used by any of these suppliers, nor has the FDA reviewed or authorized the quality of the “semaglutide” they produce.⁴ Novo Nordisk does not directly or indirectly distribute authentic semaglutide to any entity, and the quality of compounded “semaglutide” cannot be trusted.

At the end of the day, compounded “semaglutide” products have not been reviewed or approved by the FDA for safety, effectiveness, or quality. To learn more about why unapproved knockoffs can be risky, please [click here](#).

Counterfeit products

In several instances, we have discovered counterfeit medicines in the US supply chain. The US FDA has also warned patients and providers about instances of counterfeits.⁷ These products should not be used, and patients are encouraged to only obtain Novo Nordisk’s FDA-approved medicines containing semaglutide through pharmacies. To learn more about these instances or how to help identify authentic product, [click here](#).

What we’re doing to protect patient safety

Our commitment to patient safety is not just words on a page. We are continuing to take steps to ensure accurate and scientifically sound information is available to the public and healthcare professionals

Education

We continue to invest heavily in education about our products, including the FDA-approved indications, benefits, and risks. We’ve developed educational campaigns and trusted resources, like [semaglutide.com](#), where people can learn more about the risks of compounded “semaglutide,” counterfeit alerts, and how to identify FDA-approved treatment options.

We also have dedicated teams who work with reporters and other stakeholders to ensure that they have accurate information about our medicines and take measures to help correct misinformation in the press and other channels.

Accessibility

We are doubling down on our commitment to accessibility, availability, and affordability. By working to ensure broader insurance coverage, making savings available through telehealth providers integrated with NovoCare® Pharmacy, and enhancing savings offers for cash-paying patients, we are ensuring broader access to our medicines for those that need them.

Legal action

We are pursuing and intensifying legal action to secure permanent injunctions against entities that are promoting knockoff products with false and misleading claims, unlawfully selling risky compounded “semaglutide,” and attempting to convince patients, without evidence, that alternative routes of administration are as safe and effective as FDA-approved versions.

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.
Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.
Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.

What you can do

Patients

For patients who may be interested in our products, consult with a healthcare professional to evaluate your individual needs. Through shared decision-making, you and your provider will determine the appropriate medicine based on FDA-approved indications and safety and efficacy profiles.

Healthcare Professionals

We respect every healthcare professional's expertise and their right to prescribe medications based on their clinical judgement. We also ask you to prescribe medicines containing semaglutide consistent with their FDA-approved indications. Each medicine has a unique indication and safety and efficacy profiles, which are detailed in product labels and below.

Media

Our media team is available to help reporters covering our medicines and can be reached at nnmediateam@novonordisk.com. Please contact us for the most up-to-date and accurate information to inform your coverage.

About medicines containing semaglutide

Semaglutide is the primary ingredient in multiple FDA-approved prescription medicines:

Wegovy® (semaglutide) injection 2.4 mg used with a reduced calorie diet and increased physical activity:

- to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight, and
- that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg used:

- along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes
- to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease, and
- to reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults who also have chronic kidney disease

RYBELSUS® (semaglutide) tablets 7 mg or 14 mg used along with diet and exercise:

- to improve blood sugar (glucose) in adults with type 2 diabetes

To learn more about these medicines and important safety information, please visit www.semaglutide.com/medicines.



Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.
Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.
Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.

Indication and Important Safety Information for Wegovy® (semaglutide) injection 2.4 mg

What is Wegovy®?

Wegovy® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:

- to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.

Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy® is safe and effective for use in children under 12 years of age.

Important Safety Information

What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including:

- **Possible thyroid tumors, including cancer.** Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Do not use Wegovy® if:

- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy®

Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:

- have or have had problems with your pancreas or kidneys
- have type 2 diabetes and a history of diabetic retinopathy
- have or have had depression, suicidal thoughts, or mental health issues
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
- are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant
- are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.
Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.
Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy®?

Wegovy® may cause serious side effects, including:

- **inflammation of your pancreas (pancreatitis).** Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
- **gallbladder problems.** Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
- **increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas.** This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
- **kidney problems (kidney failure).** In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration
- **severe stomach problems.** Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
- **serious allergic reactions.** Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- **change in vision in people with type 2 diabetes.** Tell your healthcare provider if you have changes in vision during treatment with Wegovy®
- **increased heart rate.** Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
- **depression or thoughts of suicide.** You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you
- **food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).** Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.

Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.

Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.

Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.

The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.

Please see Prescribing Information and Medication Guide for Wegovy®.

Wegovy® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication and Important Safety Information for Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg

What is Ozempic®?

Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:

- along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes
- to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease
- to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease

It is not known if Ozempic® is safe and effective for use in children.

Important Safety Information

Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

What is the most important information I should know about Ozempic®?

Ozempic® may cause serious side effects, including:

- **Possible thyroid tumors, including cancer.** Tell your health care provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Ozempic® and medicines that work like Ozempic® caused thyroid tumors, including thyroid cancer. It is not known if Ozempic® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Ozempic® if you or any of your family have ever had MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Do not use Ozempic® if:

- you or any of your family have ever had MTC or if you have MEN 2
- you are allergic to semaglutide or any of the ingredients in Ozempic®. See symptoms of serious allergic reaction in **“What are the possible side effects of Ozempic®?”**

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
Please see Prescribing Information and Medication Guide for Wegovy®.
Please see Prescribing Information and Medication Guide for Ozempic®.
Please see Prescribing Information and Medication Guide for RYBELSUS®.

Before using Ozempic®, tell your health care provider if you have any other medical conditions, including if you:

- have or have had problems with your pancreas
- have a history of diabetic retinopathy
- have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
- are pregnant or breastfeeding or plan to become pregnant or breastfeed. It is not known if Ozempic® will harm your unborn baby or pass into your breast milk. You should stop using Ozempic® at least 2 months before you plan to become pregnant

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and other medicines to treat diabetes, including insulin or sulfonylureas.

What are the possible side effects of Ozempic®?

Ozempic® may cause serious side effects, including:

- **inflammation of your pancreas (pancreatitis).** Stop using Ozempic® and call your health care provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
- **changes in vision.** Tell your health care provider if you have changes in vision during treatment with Ozempic®
- **low blood sugar (hypoglycemia).** Your risk for getting low blood sugar may be higher if you use Ozempic® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include: dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling jittery
- **dehydration leading to kidney problems.** Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your health care provider right away if you have nausea, vomiting, or diarrhea that does not go away
- **severe stomach problems.** Stomach problems, sometimes severe, have been reported in people who use Ozempic®. Tell your health care provider if you have stomach problems that are severe or will not go away
- **serious allergic reactions.** Stop using Ozempic® and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- **gallbladder problems.** Gallbladder problems have happened in some people who take Ozempic®. Tell your health care provider right away if you get symptoms which may include: pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.

Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.

Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.

Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.

- **food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).** Ozempic® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your health care providers that you are taking Ozempic® before you are scheduled to have surgery or other procedures

The most common side effects of Ozempic® may include nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation.

Please see Prescribing Information and Medication Guide for Ozempic®.

Ozempic® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication and Important Safety Information for RYBELSUS® (semaglutide) tablets 7 mg or 14 mg

What is RYBELSUS®?

RYBELSUS® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.

- RYBELSUS® is not for use in people with type 1 diabetes
- It is not known if RYBELSUS® is safe and effective for use in children

Important Safety Information

What is the most important information I should know about RYBELSUS®?

RYBELSUS® may cause serious side effects, including:

- **Possible thyroid tumors, including cancer.** Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, RYBELSUS® and medicines that work like RYBELSUS® caused thyroid tumors, including thyroid cancer. It is not known if RYBELSUS® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people

Do not use RYBELSUS® if:

- you or any of your family have ever had MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or any of the ingredients in RYBELSUS®. See symptoms of serious allergic reaction in **“What are the possible side effects of RYBELSUS®?”**

Before using RYBELSUS®, tell your healthcare provider if you have any other medical conditions, including if you:

- have or have had problems with your pancreas or kidneys
- have a history of vision problems related to your diabetes
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
 Please see Prescribing Information and Medication Guide for Wegovy®.
 Please see Prescribing Information and Medication Guide for Ozempic®.
 Please see Prescribing Information and Medication Guide for RYBELSUS®.

- are pregnant or plan to become pregnant. It is not known if RYBELSUS® will harm your unborn baby. You should stop using RYBELSUS® 2 months before you plan to become pregnant
- are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with RYBELSUS®

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RYBELSUS® may affect the way some medicines work and some medicines may affect the way RYBELSUS® works.

How should I take RYBELSUS®?

- Take RYBELSUS® exactly as your healthcare provider tells you to
- Do not take more than 1 tablet each day
- Take RYBELSUS® by mouth on an empty stomach in the morning with a sip of plain water (no more than 4 ounces). Do not take RYBELSUS® with any other liquids besides water
- Do not split, crush, or chew. Swallow RYBELSUS® whole
- After 30 minutes, you can eat, drink, or take other oral medicines
- If you miss a dose of RYBELSUS®, skip the missed dose and go back to your regular schedule

What are the possible side effects of RYBELSUS®?

RYBELSUS® may cause serious side effects, including:

- **inflammation of your pancreas (pancreatitis).** Stop using RYBELSUS® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
- **changes in vision.** Tell your healthcare provider if you have changes in vision during treatment with RYBELSUS®
- **low blood sugar (hypoglycemia).** Your risk for getting low blood sugar may be higher if you use RYBELSUS® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. **Signs and symptoms of low blood sugar may include:** dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling jittery
- **kidney problems (kidney failure).** In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration
- **severe stomach problems.** Stomach problems, sometimes severe, have been reported in people who use RYBELSUS®. Tell your healthcare provider if you have stomach problems that are severe or will not go away
- **serious allergic reactions.** Stop using RYBELSUS® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- **gallbladder problems.** Gallbladder problems have happened in some people who take RYBELSUS®. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include: pain in your upper stomach (abdomen), yellowing of skin or eyes (jaundice), fever, and clay-colored stools



Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
 Please see [Prescribing Information](#) and [Medication Guide](#) for Wegovy®.
 Please see [Prescribing Information](#) and [Medication Guide](#) for Ozempic®.
 Please see [Prescribing Information](#) and [Medication Guide](#) for RYBELSUS®.

- **food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).** RYBELSUS® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking RYBELSUS® before you are scheduled to have surgery or other procedures

The most common side effects of RYBELSUS® may include nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation. Nausea, vomiting, and diarrhea are most common when you first start RYBELSUS®.

Please see Prescribing Information and Medication Guide for RYBELSUS®.

RYBELSUS® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References

1. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Accessed June 2025. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>. May 30, 2025.
2. Hach M, Dorthe Kot Engelund, Mysling S, et al. Impact of manufacturing process and compounding on properties and quality of follow-on glp-1 polypeptide drugs. *Pharm Res*. Published online October 8, 2024. 10.1007/ s11095-024-03771-6.
3. U.S. Food and Drug Administration (FDA). Safety Risks Associated with Certain Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Accessed June 2025. <https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>. September 27, 2024.
4. U.S. Food and Drug Administration (FDA). Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Accessed June 2025. <https://www.fda.gov/files/guidance%20documents/published/UCM602276.pdf>. March 2019.
5. Lam JKW, Cheung CCK, Chow MYT, et al. Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. *Adv Drug Deliv Rev*. 2020;160:234-243.
6. Partnership for Safe Medicines. New report reveals illegal ingredients for knockoff weight loss drugs flooding into U.S. from foreign sources, endangering patient safety. Accessed June 2025. <https://www.safemedicines.org/wp-content/uploads/2019/09/PSM-White-Paper-v1-PUBLIC-VERSION.pdf>. February 20, 2025.
7. U.S. Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. Accessed June 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain>. April 14, 2025.

Please see Important Safety Information for Wegovy®, Ozempic®, and RYBELSUS® on pages 4-10.
 Please see Prescribing Information and Medication Guide for Wegovy®.
 Please see Prescribing Information and Medication Guide for Ozempic®.
 Please see Prescribing Information and Medication Guide for RYBELSUS®.

